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ABSTRACT
Introduction: Paediatric chronic fatigue syndrome or
myalgic encephalomyelitis (CFS/ME) is a relatively
common and disabling condition, yet there is a limited
evidence base for treatment. There is good evidence
that graded exercise therapy is moderately effective in
adults with CFS/ME, but there is little evidence for the
effectiveness, cost-effectiveness, acceptability or best
method of delivery for paediatric CFS/ME. This study
aims to investigate the acceptability and feasibility of
carrying out a multicentre randomised controlled trial
investigating the effectiveness of graded exercise
therapy compared with activity management for
children/teenagers who are mildly or moderately
affected with CFS/ME.
Methods and analysis: 100 paediatric patients
(8–17 years) with CFS/ME will be recruited from 3
specialist UK National Health Service (NHS) CFS/ME
services (Bath, Cambridge and Newcastle). Patients will
be randomised (1:1) to receive either graded exercise
therapy or activity management. Feasibility analysis will
include the number of young people eligible,
approached and consented to the trial; attrition rate
and treatment adherence; questionnaire and
accelerometer completion rates. Integrated qualitative
methods will ascertain perceptions of feasibility and
acceptability of recruitment, randomisation and the
interventions. All adverse events will be monitored to
assess the safety of the trial.
Ethics and dissemination: The trial has received
ethical approval from the National Research Ethics
Service (South West—Frenchay 15/SW/0124).
Trial registration number: ISRCTN23962803; Pre-
results.
INTRODUCTION
Chronic fatigue syndrome or myalgic enceph-
alomyelitis (CFS/ME) in children is relatively
common, affecting between 0.1% and 2% of
secondary school-aged children.1–4 CFS/ME
is deﬁned as ‘generalised fatigue, causing dis-
ruption of daily life, persisting after routine
tests and investigations have failed to identify
an obvious underlying “cause”’.5 6 National
Institute for Health and Care Excellence
(NICE) guidelines recommend a minimum
3-month duration of fatigue before making a
diagnosis in children.5
NICE recommends that children with CFS/
ME are offered either cognitive–behavioural
therapy (CBT), graded exercise therapy
(GET) or activity management.5 GET stabi-
lises physical activity levels, before gradually
increasing at a manageable rate.5 7–11 Activity
management establishes a baseline for all the
activities (mainly cognitive, such as school and
homework, in children and adolescents),
which is then increased.5 12 There is good evi-
dence for the effectiveness of CBT in children
with CFS/ME;13–15 however, there is little evi-
dence for the effectiveness of GET in children
and adolescents, although GET is moderately
effective in adults.7 There is also limited evi-
dence on the acceptability of GET for chil-
dren and adolescents with CFS/ME or on the
best method for delivering these interventions
in terms of intensity (frequency of sessions)
and length of interventions (number of ses-
sions and length of time for interventions).
Strengths and limitations of this study
▪ This feasibility study is the first trial to investi-
gate graded exercise therapy in children with
chronic fatigue syndrome or myalgic encephalo-
myelitis (CFS/ME) in the outpatient setting.
▪ Integrated qualitative methodology is being used
to optimise recruitment and retention, and to
investigate the feasibility and acceptability of the
study processes and interventions.
▪ This is a multicentre study which will test the
feasibility of running this trial in different
National Health Service (NHS) settings.
▪ The participants and clinicians will not be
blinded to allocation.
▪ Participant outcomes are self-reported.
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In addition to estimating study parameters such as the
willingness of participants to be randomised and the
number of eligible patients,16 feasibility studies can be
used to improve recruitment and retention by audio-
recording recruitment discussions, evaluating informa-
tion exchange and training those who recruit to the
study.17 18 Integrated qualitative methodology can also
be used to investigate participants’ view of interventions
and study methodology, providing an opportunity to
improve them prior to the full trial.19
In this study, we will determine whether it is accept-
able and feasible to deliver GET compared with activity
management in a multicentre randomised controlled
trial (RCT). The trial is designed as a pragmatic trial as
we are interested in the effectiveness of interventions
delivered in routine practice.20 Integrated qualitative
methods will be used to optimise recruitment retention
and the delivery of the interventions, and to investigate
the best method for measuring outcomes.
AIMS AND OBJECTIVES
To ascertain the feasibility and acceptability of conduct-
ing an RCT to investigate the effectiveness and cost-
effectiveness of GET compared with activity manage-
ment for the treatment of CFS/ME in children. We will
use the information to inform the design of a full-scale,
adequately powered trial. The speciﬁc objectives are to:
1. Assess the number of eligible children and adoles-
cents, the number of children and adolescents
approached, the number recruited and the number
retained in the ﬁrst 6 months of the study.
2. Identify barriers and facilitators to trial recruitment
with a view to addressing barriers where possible.
3. Explore issues of retention and understand why
people drop out of the study.
4. Assess the acceptability (satisfaction and adherence)
of GET and activity management.
5. Assess the feasibility and acceptability of using accel-
erometers to measure physical activity in children
and adolescents with CFS/ME.
6. Evaluate whether the two interventions are distinct
and being delivered in a consistent manner across
centres.
METHOD
Study design
This study started in September 2015 and recruitment is
expected to ﬁnish in August 2016. This is a feasibility
RCT with integrated qualitative methods.
Participants and recruitment
Potential participants will be identiﬁed by the clinician
conducting the ﬁrst assessment at specialist paediatric
CFS/ME services in Bath, Newcastle and Cambridge.
The clinician will provide information about the study
and obtain written assent/consent for a member of the
research team to talk to the child and parent/carers
about the study and for this discussion to be recorded.
Potential participants can either meet the recruiting
researcher in the hospital on the day of the initial assess-
ment or discuss the study at a later date on the phone.
At the start of the recruitment to trial discussion, the
recruiter will conﬁrm assent/consent for the discussion
and check that the parent continues to be happy to have
the discussion audio-recorded. The recruiting researcher
will then discuss and provide further information about
the Managed Activity Graded Exercise iN Teenagers and
pre-Adolescents (MAGENTA) trial, including the study
design, interventions, participant burden and the poten-
tial risks and beneﬁts of taking part.
Children and parents who wish to take part in the
study can either complete the written study assent/
consent forms with the recruiter at the end of the dis-
cussion, returning them via post, scan the forms and
email them electronically or sign the web-based consent
form provided through the University of Bristol’s data
capture system (Research Electronic Data Capture
(REDCap), http://project-redcap.org/). A key aim of
the feasibility trial is to ascertain the usefulness of the
consent procedures.
Inclusion/exclusion criteria
Children and adolescents will be eligible for inclusion if
they are given a diagnosis of CFS/ME (made using
NICE guidance5) and aged between 8 and 17 years
inclusive.
Children and adolescents will be excluded if they are
severely affected. NICE deﬁnes severe CFS/ME as indivi-
duals who are unable to do activity for themselves, or
carry out minimal daily tasks only, have severe cognitive
difﬁculties and depend on wheelchair for mobility;5 or
are referred for CBT at their ﬁrst clinical assessment; or
are unable to attend clinical sessions. Eligibility assess-
ment will be carried out by the clinician at assessment
and conﬁrmed by the recruiting researcher.
Randomisation and allocation
Once the recruiter has received the signed assent/
consent forms, they will use the automated telephone/
web randomisation service operated by the Bristol
Randomised Trials Collaboration. Allocation (1:1) will
use minimisation to facilitate balance by age and gender,
and retain a random component to prevent accurate
prediction of allocation. Owing to the nature of the
interventions, it is not practical to keep either the family
or the clinical service blind to intervention allocation. If
allocation is done during the recruitment appointment,
families can choose to know the allocation immediately
or be told later by phone or letter (if told via phone, the
discussion will be audio-recorded with assent/consent
from the parent/child). The recruiter then informs the
clinical service who writes to the parent/child with their
appointment details. The child’s general practitioners
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(GPs) will be told what intervention they will receive as
part of routine clinical practice.
Sample size
An estimated 380 children and adolescents are assessed
per annum in the three centres (Bath/Bristol 300,
Cambridge 50, Newcastle 30). Estimates based on the
Specialist Medical Intervention and Lightning Evaluation
(SMILE) trial12 suggest 60% will be eligible, of which 40–
50% will be recruited. We therefore estimate that recruit-
ment of 100 will take ∼12 months.
Recruiting 100 children from 430 eligible children
approached will give a 95% CI of 20% to 28% for an
estimated recruitment rate of 24% (0.6 eligible×0.4 con-
senting), which is acceptably precise for planning the
main study recruitment.
Clinical interventions
Both interventions will be delivered in an outpatient
setting. During clinical sessions, clinicians and patients
develop collaborative activity plans, which children and
adolescents then implement in the community (includ-
ing home and school environments). Children and ado-
lescents will be advised to use paper diaries/apps to
assist with monitoring and recording of activity levels. In
both arms, children and adolescents, their parents and
the clinician providing intervention will choose the
number of clinical sessions (between 8 and 12) and the
frequency of appointments (every 2–6 weeks) within a
maximum length of treatment of 1 year.
In both arms, clinicians will be encouraged to offer
routine5 advice about sleep, medication use, symptom
control and setbacks at the assessment and during inter-
vention sessions.
Participants who develop anxiety or depression that
requires treatment during the trial follow-up period will
be offered up to 12 sessions of CBT delivered as individ-
ual sessions every 2 weeks by a CFS/ME specialist clinical
psychologist.
Participants will be allowed to either discontinue the
intervention or withdraw from the trial at any time. If
parents or clinicians request cross-over to the other
intervention arm, we will encourage them to try the ori-
ginal allocation for 6 months (the primary outcome).
Any cross-over will be recorded.
Arm 1: activity management
This arm will be delivered by CFS/ME specialists. As
activity management is currently being delivered in all
three services, clinicians will not require further train-
ing; however, they will receive guidance on the manda-
tory, prohibited and ﬂexible components (see online
supplementary appendix 1). Clinicians therefore have
ﬂexibility in delivering the intervention within their
National Health Service (NHS) setting. Activity manage-
ment aims to convert a ‘boom–bust’ pattern of activity
(lots 1 day and little the next) to a baseline with the
same daily amount before increasing the daily amount
by 10–20% each week. For children and adolescents
with CFS/ME, these are mostly cognitive activities:
school, schoolwork, reading, socialising and screen time
(phone, laptop, TV, games). Those allocated to this arm
will receive advice about the total amount of daily activ-
ity, including physical activity, but will not receive speciﬁc
advice about their use of exercise, increasing exercise or
timed physical exercise.
Arm 2: graded exercise therapy (GET)
This arm will be delivered by referral to a GET-trained
CFS/ME specialist who will receive guidance on the man-
datory, prohibited and ﬂexible components (see online
supplementary appendix 1). They will be encouraged to
deliver GET as they would in their NHS setting.20 Those
allocated to this arm will be offered advice that is focused
on exercise with detailed assessment of current physical
activity, advice about exercise and a programme includ-
ing timed daily exercise. The intervention will encourage
children and adolescents to ﬁnd a baseline level of exer-
cise which will be increased slowly (by 10–20% a week, as
per NICE guidance5 and the Pacing, graded Activity and
Cognitive behaviour therapy – a randomised Evaluation
(PACE)12 21). This will be the median amount of daily
exercise done during the week. Children and adolescents
will also be taught to use a heart rate monitor to avoid
overexertion. Participants will be advised to stay within
the target heart rate zones of 50–70% of their maximum
heart rate.5 7
For further details about both intervention arms,
please see online supplementary appendix 1.
Integrated qualitative methods
Qualitative research methods will be integrated into the
feasibility study to optimise the recruitment process and
investigate acceptability of the interventions and wider
trial processes.
Trial processes
The recruiting researcher will receive a training session
on the two interventions and will be encouraged to
provide a balanced description of each (by spending an
equal amount of time discussing the beneﬁts and draw-
backs of both intervention arms). To identify recruit-
ment difﬁculties and improve recruitment,18 we will
audio-record (with assent/consent) recruitment discus-
sions. A sample of these will be analysed at regular inter-
vals to explore information provision, recruitment
techniques, patient intervention preferences and trial
participation decisions. If analyses of the audio-
recordings identify issues that appear to be impacting
on trial recruitment, then feedback and training will be
offered to the recruiter, the content of which will
depend on the ﬁndings.
If the number of eligible patients recruited is lower
than expected, or if there are differences in the percent-
age recruited between centres, we may undertake
in-depth interviews with the clinical and recruitment
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staff and analyse screening logs to examine possible pro-
blems with patient pathways in the different centres.
We will undertake in-depth interviews with parents
and their children and adolescents to understand their
views and experiences of trial processes. This will
include provision and acceptability of patient informa-
tion and reasons for accepting or declining participa-
tion. We are particularly interested in understanding
barriers to participation and with assent/consent will
interview those who choose not to participate in the
trial, who drop out of trial follow-up or who do not
accept intervention allocation at randomisation. We will
interview children and adolescents and their parents
about their use of the accelerometer, whether it is an
acceptable device to wear and whether there are particu-
lar issues we need to consider in this patient group for
the full trial.
Trial interventions
Intervention sessions will be routinely audio-recorded,
with consent, to enable us to test that activity manage-
ment and GET are truly distinct, and to ensure that the
interventions are delivered in a consistent manner across
centres. The delivery of up to 10 interventions, in both
arms in each centre, will be observed. Sessions delivered
early in the feasibility study will be observed initially,
with further sessions being sampled depending on the
analysis of these initial observations. Detailed notes will
be taken, including the context, intensity and variability
of intervention delivery, to understand how interventions
are delivered and received in practice and to help inter-
pret outcomes (eg, variation between subgroups).
We will interview parents and their children and ado-
lescents about both interventions, including any prior
exposure to the study interventions; beliefs, expectations
and preferences about the interventions before assign-
ment; their experiences and acceptability of the inter-
ventions; use of heart rate monitors (including whether
they increase or decrease anxiety); and their views of
the number of intervention sessions required.
Participants will be recruited from all three centres to
assess differences in implementation between settings.
We will interview clinicians delivering both interven-
tions in each centre to ascertain their views on the feasi-
bility of delivery (particularly focusing on younger
children), changes that need to be made to the inter-
ventions offered, optimal frequency of appointments
and technical problems with using heart rate monitors.
Interviews with clinicians, participants and families will
be semistructured using a topic guide to ensure that
they cover the same issues while allowing new issues of
importance to emerge. Sampling for interviews will
ensure that a range of informants (in terms of age,
gender, ethnicity, geographical location, socioeconomic
circumstances and disease severity) are included
(maximum variation sampling), and that people with
particular characteristics of interest can be targeted to
follow-up and develop emerging ﬁndings (theoretical
sampling). Sample size will be determined by data satur-
ation, that is, when no new themes are being uncov-
ered.22 It is anticipated that up to 20 patients, 15 parents
and 10 clinicians involved in recruitment and/or deliver-
ing the interventions will be interviewed at a location of
their choice. We estimate that up to 45 patient, parent
and clinical staff interviews will be sufﬁcient to deter-
mine whether it is feasible and acceptable to take the
study to full trial, and to identify ways to improve study
processes. All discussions will be audio-recorded with
assent/consent using encrypted software, transcribed
verbatim and anonymised.
Outcomes measures
Feasibility outcomes measurement
We will use quantitative and qualitative data to deter-
mine the feasibility and acceptability of a full-scale multi-
centre RCT. Findings will be fed back to the research
team to improve the design, conduct and organisation
of the main trial.
Quantitative data will include the number of children
and adolescents who were eligible, approached, con-
sented and retained in the study; the completeness of
questionnaire data at baseline assessment and follow-up;
the percentage of children and adolescents providing
usable accelerometer data; and the proportion of partici-
pants who found their allocated intervention acceptable
and adhered to the intervention programme (propor-
tion of planned sessions attended) in each arm. The
number of participants in each arm referred for CBT
will be ascertained from hospital records.
Quantitative analysis
The percentage recruited of those eligible will be calcu-
lated from the screening log data and presented with
95% CI. Retention will be estimated as the percentage of
recruited children and adolescents reaching the primary
6-month follow-up point, who provide key outcome mea-
sures (the Chalder Fatigue Scale and the 36-Item
Short-Form Physical Functioning Scale (SF-36 PFS)) at
that assessment point. The retention estimates will be
presented for each intervention arm with 95% CIs. We
will record the number of booked intervention sessions
where participants did not attend or where there was a
late cancellation (within 24 hours). We will assume that
those who did not attend (or cancelled within 24 hours)
three or more consecutive appointments or 50% of
appointments did not ﬁnd the interventions acceptable.
We will calculate the proportion of children and adoles-
cents who wear the accelerometer and provide usable
data. We will assume periods of 60 min or more with zero
readings as ‘non-wear’ time. Participant’s data will be
included if they provide two or more weekdays of data
with at least 500 min of data between 6:00 and 23:00.
Mean minutes of weekday, light and moderate-to-vigorous
physical activity (MVPA) per day will be established using
the Evenson thresholds,23 which have been shown to be
the most accurate for this age group.
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We will collect the number, frequency and length of
clinical sessions for each participant.
At 12 months, we will assess whether the trial should
continue to a full trial. The full trial is unlikely to be
feasible in the format considered here if any of the fol-
lowing apply:
1. Less than 70 children and adolescents have been
recruited (∼70% of the target) and if the qualitative
data collected suggest that recruitment cannot be
improved any further.
2. The 6-month follow-up is <80% and if the qualitative
data suggest that follow-up rates cannot be improved
any further.
3. Data suggest the interventions are not acceptable to
children and/or their parents.
4. If the Data and Safety Monitoring Committee
(DSMC) and the Trial Steering Committee (TSC)
recommend the trial is stopped for safety reasons.
Fidelity of GET and activity management: we will monitor
protocol adherence and evaluate whether the two inter-
ventions are distinct and being delivered in a consistent
manner across centres. Two clinicians, from centres
other than that in which the session was delivered, will
listen to a random sample (∼10%) of the audio-
recorded sessions in a blinded fashion and rate them on
a ﬁve-point Likert scale as being GET or activity manage-
ment or a mixture of the two using the mandatory, pro-
hibited and ﬂexible elements for each intervention. We
will estimate intervention ﬁdelity as the percentage of
sessions in each intervention arm which were correctly
identiﬁed by the clinicians assessing recordings.
Health economic measures: we will assess the feasibility of
using routine data to gather information on the initial
costs of the GET and activity management interventions
and other specialist services (eg, CBT) offered to chil-
dren and adolescents. We will test the acceptability of
collecting healthcare resource use data at 6 and
12 months to estimate the other CFS/ME-related costs
to the NHS, other government agencies and the
broader impact on family expenses, productivity and
informal care.
Safety outcomes: we will collect all serious and non-
serious adverse events deﬁned as any clinical change or
illness reported at clinic or postal follow-up. In addition,
we will deﬁne a serious deterioration in health as a
decrease ≥20 in SF-36 PFS or scores of ‘much’ or ‘very
much worse’ on the Clinical Global Impression Scale;
clinician-reported serious deterioration in health; or
withdrawal from intervention because of feeling worse.
Safety outcomes will be analysed by the DSMC at
10 months to ensure that neither intervention arm is
having a detrimental effect. The DSMC will include
three independent experts in CFS/ME, statistics and
trials and will report to the TSC.
Clinical outcome measures
Patient-reported outcomes will be collected at baseline,
6 and 12 months postrandomisation (see table 1).
Both parents will be asked to complete three inventor-
ies online at baseline, 6 and 12-month follow-up, includ-
ing socioeconomic status (baseline only); an adapted
four-item Work Productivity and Activity Impairment
Questionnaire (General Health V2.0 [WPAI:GH]);29 and
an adapted existing healthcare resource use question-
naire to measure health service use (eg, GP or specialist
care), educational service (eg, school counsellor) and
travel costs. The acceptability of these inventories in this
participant group has been tested.19 Information from
the specialist services medical records will be extracted
to identify referrals for additional CBT or referrals to
Child and Adolescent Mental Health Services within
12 months of randomisation.
If questionnaires are not returned, an email reminder
(or postal reminder if the participant does not have inter-
net access) will be sent after 1 week. If outcomes are still
not completed, a further email (or postal) reminder will
be sent with a link to a reduced number of questions con-
taining just the Chalder Fatigue Scale, the SF 36 PFS and
the EQ-5D-Y as these were shown to be acceptable in our
previous trial.19 If this is not completed, we will make up
to four follow-up telephones calls or emails and offer to
collect the primary outcome data over the phone.
In addition to questionnaire measures, participants in
both trial arms will be asked to wear an accelerometer
(GT3X+) to measure physical activity for 7 days within
1 month of randomisation and at 3 and 6-month
follow-up. During this 7-day period, participants will be
instructed to wear the device for the entirety of the day.
Accelerometers will be posted to participants with
instructions. Participants will be asked to complete a log
of wear time (time worn and time taken off).
Accelerometers are small, matchbox-sized devices that
measure physical activity. They have been shown to
provide reliable indicators of physical activity among
children and adults.30 The accelerometer data will be
processed to identify mean minutes of sedentary, light
and moderate-to-vigorous-intensity physical activity per
day using established accelerometer cut-off points and
Table 1 Data routinely collected at assessment.
Questionnaire data collected at baseline, 6 and 12 months
Assessment data Questionnaires
Age Chalder fatigue24
Sex Physical function (SF-36)25
Ethnicity
(drop-down list)
Hospital Anxiety Depression
Scale26
School attendance Spence Children’s Anxiety
Scale27
Symptoms list Pain Visual Analogue Scale
CDC and NICE criteria Quality of life (EQ-5D-Y28)
Months of illness Clinical Global Impression Scale*
Comorbid conditions
*Collected at 6-month and 12-month follow-up only.
CDC, Centers for Disease Control; NICE, National Institute for
Health and Care Excellence.
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protocols.23 31 The mean accelerometer counts per
minute, which provides an indication of the volume of
physical activity in which the participant engages, will
also be calculated using established methods.7 23 See
ﬁgure 1 for the study ﬂow diagram.
QUALITATIVE DATA ANALYSES
Analysis of the audio-recordings, observations and inter-
views will be an ongoing and iterative process commen-
cing soon after data collection. Emerging ﬁndings will
inform further sampling and data collection. A multiple
analytical approach will be employed, with the use of
NVivo to assist with data management and analysis.
Interview transcripts and observation notes will be sys-
tematically assigned codes and analysed thematically
using techniques of constant comparison to identify
common themes (thematic analysis). Individuals exhibit-
ing contrasting attitudes (negative cases) will be studied
in detail. The perspectives of the individuals will be para-
mount, with careful account taken of the context within
which the discussion takes place.
Content analytic methods will be used to describe in a
structured manner what was said by whom and how
often in the audio-recordings of recruitment and inter-
vention sessions. Thematic analysis will also be applied
Figure 1 Study flow diagram detailing participant flow through the study-related interventions and data collection procedures.
CDC, Centers for Disease Control; NICE, National Institute for Health and Care Excellence.
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to the data to identify common or divergent themes, as
described above, particularly focusing on the impact of
statements by the recruiter/clinician on patients and
parents. Conversation analysis will be used to focus in
great detail on certain sections of the audio-recordings,
for example, in the speciﬁc interactions during which
randomisation is offered.
Data analyses will be undertaken primarily by the
qualitative researcher. To check coding reliability, other
members of the team will independently analyse a pro-
portion of transcripts and compare ﬁndings.
ETHICS AND DISSEMINATION
Ethical considerations
GET, CBT and activity management are recommended
as treatments in NICE guidance for CFS/ME;5 however,
there is no evidence that GET is effective or safe in chil-
dren and adolescents. CFS/ME is different in children
and adults with different risk factors, course and
outcome.32 It is therefore not possible to extrapolate the
results from adult studies to children. A trial in children
is therefore required.
At the moment, CBT has the best evidence for treat-
ment efﬁcacy. We have not included CBT as the control
arm because clinicians would not be in equipoise in ran-
domising children to CBT or GET. CBT will continue to
be offered to young people who develop mood pro-
blems after randomisation and can be accessed in add-
ition to either treatment arm. We will analyse referral to
CBT as a secondary outcome.
As the participants will be aged 8–17 years, we have
put in place rigorous procedures for gaining informed
assent/consent from children and adolescents and their
parents. Families will be given as long as they need
before giving assent/consent within the conﬁnes of the
study. We will then obtain further assent/consent prior
to each interview and prior to recording interventions to
check that children and adolescents and their parents
continue to be willing to participate.
Data protection/confidentiality
Participants will be allocated a unique seven-digit
research identiﬁcation number prior to assessment for
screening logs and questionnaires. Assent/consent
forms containing personal information will be kept in a
locked ﬁling cabinet in a locked ofﬁce within the
University of Bristol. A list of names and corresponding
identiﬁcation numbers will be kept separately and
securely on a password-protected NHS server.
Data will be entered into REDCap, a secure system used
by multiple institutions for large multicentre studies.
Assessment data will be entered by the research team.
Participants will be encouraged to provide follow-up data
through REDCap using a secure password-protected
login, but will be able to provide data by post if they do
not have internet access.
Dissemination of research findings
Research ﬁndings will be disseminated through peer-
reviewed research journals, conferences and patient
organisations.
Ethics approval
The trial has been reviewed and granted approval by the
National Research Ethics Service Committee (South
West—Frenchay 15/SW/0124).
Public and patient involvement
A Patient Advisory Group (PAG) has been involved
throughout the development of this protocol and will
remain involved throughout the running of the trial,
with PAG meetings being held every 6 months. Minutes
from the PAG group will be disseminated to the Study
Steering Committee and the Trial Management Group.
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